Startseite Kongressberichte 2020 Virtual Edition of the 25th Annual Congress of the European Hematology Association Oral Sessions Chronic Lymphoid Neoplasms CLL: CLL:

CLL - Targeted therapy I

The results confirm the superior efficacy with longer progression-free survival and deep remissions after fixed-duration VenG compared to ClbG. This suggests that long-term benefits are maintained for over two years after completing 12 cycles of VenG.

————————————————————————————————————————————————————————
 
 
Arnon P. Kater, Önder Arslan, Fatih Demikran, et al.
 
The authors of the abstract conclude: 
This Phase 3b study confirms VEN monotherapy can achieve deep responses (CR and/or uMRD) and has a tolerable and manageable safety profile in patients with R/R CLL. The duration of PFS was longer in patients who had uMRD, had better iwCLL response, and for BCRi-N vs BCRi-EXP patients. 
 
————————————————————————————————————————————————————————
 
 
Henriette Huber, Simone Edenhofer, Julia von Tresckow, et al.
 
The authors of the abstract conclude: 
The GIVe triple combination regimen is a promising 1st line treatment option for pts with high risk CLL yielding encouraging response rates (58.5% CR/CRi (CI: 42.1-73.7, p<0.001)) and 80.5% uMRD.
————————————————————————————————————————————————————————
 
 
Tanya Siddiqi, Constantine S. Tam, John N. Allan, et al.
 
The authors of the abstract conclude: 
Ibr + Ven represents an all-oral, once-daily, chemotherapy-free regimen that confers high rates of uMRD in PB and BM in first-line treatment of CLL, with highly concordant uMRD results between PB and BM. Results from CAPTIVATE validate the preclinical synergism of this combination. Ibr lead-in substantially reduced Ven-related TLS risk and need for intensive monitoring/hospitalization. The safety profile of Ibr + Ven was favorable with a low rate of discontinuation due to AEs and 90% completing all planned treatment with 3 cycles of Ibr and 12 cycles of Ibr + Ven combination. ————————————————————————————————————————————————————————
 
 
Paolo Ghia, Andrzej Pluta, Malgorzata Wach, et al.
 
The authors of the abstract conclude: 
Final ASCEND results with additional follow-up confirm earlier findings and support the favorable efficacy and safety of acalabrutinib compared with standard-of-care regimens in patients with R/R CLL.